Page 6 - Mol Biol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been basically under control in China since March 2020，but the import of domestic SARS-CoV-2 have begun to increase. This study reported the first case of asymptomatic SARS-CoV-2 infection imported from Spain into Sichuan Province, China, on March 11, 2020. The infected male had a body temperature of 37.5°C, normal blood oxygen saturation levels, and a computed tomography (CT) examination showed that his lungs had no shadows. However, a throat swab from the subject tested positive for SARS-CoV-2 ...

- Cell counting What is cell culture? Cell culture refers to the removal of cells from an animal or plant and subsequent cultivation in an artificial environment for scientific research. The first cell culture techniques were developed over 100 years ago and since then have contributed to tremendous breakthroughs in science. Today, it is a fundamental tool used in laboratories around the world for studying the normal physiology and biochemistry of cells, mechanisms underlying disease and effects of drugs and toxic compounds. It is also used in drug screening and development and large-scale ma...

F. Hoffmann-La Roche Ltd: European Commission approves Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer 1,2,3 administered under the skin in just minutes compared to hours with intravenous ( IV) infusion of Perjeta plus Herceptin 4,5,6 Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered non-inferior 7 Basel, 23 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo , a fixed-dose combination...

F. Hoffmann-La Roche Ltd European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs 1,2,3 administered under the skin in just minutes compared to hours with intravenous ( IV) inf...